Malignant Insulinoma: Effects of a Somatostatin Analog (Compound 201-995) on Serum Glucose, Growth, and Gastro-Entero-Pancreatic Hormones
Authors: KWAME OSEI
Journal: Annals of Internal Medicine (1985)

Brief Reports1 August 1985Malignant Insulinoma: Effects of a Somatostatin Analog (Compound 201-995) on Serum Glucose, Growth, and Gastro-Entero-Pancreatic HormonesKWAME OSEI, M. D., THOMAS M. O'DORISIO, M.D.KWAME OSEI, M. D.Search for more papers by this author, THOMAS M. O'DORISIO, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-103-2-223 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptVarious therapies have been used to treat patients with active malignant insulinoma (1-3), which comprises 10% of all beta-cell tumors of the pancreas (1). Somatostatin, a tetradecapeptide found in the hypothalamus and gastro-entero-pancreatic system, suppresses several endocrine hormones (4). However, because of the short halflife (5 to 10 minutes) of endogenous somatostatin, several analogs with longer-acting properties have been synthesized (5). Recently, compound 201-995 (Sandoz Pharmaceutical, Inc., East Hanover, New Jersey), an octapeptide with a 10 to 20 times longer half-life and a 50 to 100 times greater potency has become available in United States. We report the use of...References1. BRODER L and CARTER S. Pancreatic islet cell carcinoma: II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med. 1973;19:108-18. LinkGoogle Scholar2. GRABER A, PORTE D, and WILLIAMS R. Clinical use of diazoxide and mechanism for its hyperglycemic effects. Diabetes. 1966;15:143-8. CrossrefMedlineGoogle Scholar3. OSEI K, FALKO J, NELSON K, and STEPHENS R. Diabetogenic effect of Pentamidine: in vitro and in vivo studies in a patient with malignant insulinoma. Am J Med. 1984;77:41-6. CrossrefMedlineGoogle Scholar4. ADRIAN T, BARNES A, and LONG R. The effect of somatostatin analogs on secretion of growth, pancreatic and gastrointestinal hormones. J Clin Endocrinol Metab. 1981;53:675-81. CrossrefMedlineGoogle Scholar5. SHEPPARD M, SHAPIRO B, PINSTONE B, KRONHEIM S, BERELOVITZ M, and GREGORY M. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab. 1979;48:50-3. CrossrefMedlineGoogle Scholar6. SHERMAN B, PEK S, FAJANS S, FLOYD J, and CONN J. Plasma proinsulin in patients with functioning pancreatic islet cell tumor. J Clin Endocrinol Metab. 1972;35:271-80. CrossrefMedlineGoogle Scholar7. BAR R, GORDEN P, ROTH J, and SIEBERT C. Insulin receptors in patients with insulinoma: changes in receptor affinity and concentration. J Clin Endocrinol Metab. 1977;44:1210-3. CrossrefMedlineGoogle Scholar8. KRAENZLIN M, CH'NG J, WOOD S, and BLOOM S. Can inhibition of hormone secretion be associated with endocrine tumor shrinkage [Letter]? Lancet. 1983;2:1501. CrossrefMedlineGoogle Scholar9. JONES C, MILLER J, LAWRIE C, SUMMER D, and REID J. Specific inhibition of aldosterone responses to endogenous and exogenous angiotensin II by somatostatin. Clin Endocrinol. 1984;21:279-84. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: KWAME OSEI, M. D.; THOMAS M. O'DORISIO, M.D.Affiliations: The Ohio State University College of Medicine Columbus, Ohio. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySomatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemiaHypoglycemia and Hypoglycemic SyndromesInsulinoma: Literature’s Review (2)Neuroendocrine TumorsHypoglycemia and Hypoglycemic SyndromesUse of Octreotide to Treat Prolonged Sulfonylurea-induced Hypoglycemia in a Patient with Chronic Renal FailureThe clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?Embolization and chemoembolization therapy for neuroendocrine tumorsOctreotide in HyperinsulinismEvaluation of the long-acting somatostatin analogue Octreotide in the management of insulinoma in three dogsOctreotide Effect on Ovarian Morphology in Insulin-Resistant PCOS Patients Following Six-Month Decapeptyl TreatmentRecurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumorMechanisms of somatostatin action in RINm5F cells in culture: Preliminary evidence for possible altered G protein functionPreventive effects of octreotide (SMS 201-995) on diabetic ketogenesis during insulin withdrawal.Biology of pancreatic cancer.The Molecular Biology of Pancreatic AdenocarcinomaTherapeutic strategies in the management of endocrine GEP tumoursThe Use of the Long-Acting Somatostatin Analogue, Octreotide Acetate, in Patients with Islet Cell TumorsFailure of Somatostatin Analogue Sms 201–995 to Control Cushing's Syndrome Due to Ectopic Release of Acth from a Bronchial CarcinoidTreatment of Endocrine Tumors of the PancreasUse of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumorsInsulin-Producing Islet Cell TumorsSomatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the GutPhillip Gorden, MD, Richard J. Comi, MD, Paul N. Maton, MD, Vay Liang W. Go, MDCongenital Disorders of the Kidneys and TumorsTherapy of the Malignant Carcinoid Syndrome and Metastatic Islet Cell CarcinomaSandostatin® and Gastroenteropancreatic Endocrine Tumors — Therapeutic CharacteristicsTumors of the Gastroenteropancreatic AxisSandostatin®: Assay and Efficacy in VIPoma and InsulinomaSomatostatin and its analogues in the therapy of gastrointestinal diseaseOctreotide: A Synthetic Analog of SomatostatinIslet Cell Tumors Metastatic to the Liver: Effective Palliation by Sequential Hepatic Artery EmbolizationJAFFER A. AJANI, M.D., C. HUMBERTO CARRASCO, M.D., CHUSILP CHARNSANGAVEJ, M.D., NAGUIB A. SAMAAN, M.D., BERNARD LEVIN, M.D., SIDNEY WALLACE, M.D.Somatostatin and Octreotide: Literature Review and Description of Therapeutic Activity in Pancreatic NeoplasiaOctreotide: Entering the New Era of Peptidomimetic TherapyAcromegaly from ectopic growth hormone-releasing hormone secretion by a malignant carcinoid tumor.Successful treatment with long-acting somatostatin analogue SMS 201–995Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201–995) on plasma thyroid-stimulating hormone in normal human subjectsInhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995Long-term treatment of refractory neonatal hypoglycemia with long-acting somatostatin analogPREVENTION OF HYPOGLYCAEMIA IN A PATIENT WITH PANCREATIC MICROADENOMATOSIS BY A LONG-ACTING SOMATOSTATIN ANALOGUE SMS 201-995Treatment of diabetic diarrhea and orthostatic hypotension with somatostatin analogue SMS 201–995Treatment of Metastatic Islet Cell Carcinoma with a Somatostatin Analogue (SMS 201-995)LARRY K. KVOLS, M.D., MARTIN BUCK, M.D., CHARLES G. MOERTEL, M.D., ALLAN J. SCHUTT, M.D., JOSEPH RUBIN, M.D., MICHAEL J. O'CONNELL, M.D., RICHARD G. HAHN, M.D.Somatostatin.Response of Thyrotropin-Secreting Pituitary Adenomas to a Long-Acting Somatostatin AnalogueClinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndromeRole of peptide radioimmunoassay in understanding peptidepeptide interactions and clinical expression of gastroenteropancreatic endocrine tumorsRebound hypergastrinemia after cessation of a somatostatin analogue (SMS 201-995) in malignant gastrinomaPharmacological studies of somatostatin and somatostatin-analogues: Therapeutic advances and perspectivesGrowth HormoneTreatment of Gut-Associated Neuroendocrine Tumors with the Long-Acting Somatostatin Analog, SMS 201-995Maligne Tumoren des endokrinen PankreasMiscellaneous hormones and prostaglandinsTreatment of Resistant Acromegaly with a Long-Acting Somatostatin Analogue (SMS 201-995)LUClNDA B. BARNARD, M.D., GRANTHAM WILLIAM G., M.D., Ph.D., PRESTON LAMBERTON, M.D., THOMAS M. O'DORISIO, M.D., IVOR M. D. JACKSON, M.R.C.P.Gut endocrinology: Clinical and therapeutic impactSomatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromesTreatment of postprandial hypotension with a somatostatin analogue (SMS 201-995)TREATMENT OF AUTONOMIC NEUROPATHY WITH A SOMATOSTATIN ANALOGUE SMS-201-995Treatment of Inoperable Glucagonoma with the Long-Acting Somatostatin Analogue SMS 201–995Modulation of functional gastrointestinal endocrine tumors by endogenous and exogenous somatostatinEffect of chronically administered somatostatin on the nude mouse 1 August 1985Volume 103, Issue 2Page: 223-225KeywordsGastroenterology and hepatologyHormonal therapyHormonesHypothalamusInsulinomaPancreasPatientsResearch laboratoriesSomatostatinVeteran care ePublished: 1 December 2008 Issue Published: 1 August 1985 PDF downloadLoading ...